预约演示
更新于：2025-03-08
Tagraxofusp-ERZS
更新于：2025-03-08
概要
基本信息
药物类型 融合蛋白 |
别名 Diphtheria toxin-il-3 fusion protein targeting IL-3 receptor、Diphtheria-toxin-interleukin-3-fusion-protein、Tagraxofusp + [8] |
靶点 |
作用机制 CD123抑制剂(白细胞介素-3受体α亚基抑制剂) |
在研适应症 |
最高研发阶段批准上市 |
首次获批日期 美国 (2018-12-21), |
最高研发阶段(中国)- |
特殊审评孤儿药 (美国)、孤儿药 (澳大利亚)、突破性疗法 (美国) |
登录后查看时间轴
结构/序列
Sequence Code 453129448
来源: *****
关联
22
项与 Tagraxofusp-ERZS 相关的临床试验NCT06561152
Tagraxofusp and Low-Intensity Chemotherapy for the Treatment of CD123-Positive Relapsed or Refractory Acute Myeloid Leukemia (AML)
NCT06498973
CD123 Antibody Toxin Congregate (CD123 ATC; Tagraxofusp) Combined With Azacitidine for Maintenance Therapy Post Allogeneic Hematopoietic Cell Transplantation for Patients With CD123-Positive Malignant
NCT06456463
A Phase II Multicenter Open-label Trial of Tagraxofusp (Tag) in Combination With Venetoclax and Azacitidine (Ven/Aza) in Adults With Previously Untreated CD123+ Acute Myeloid Leukemia (AML) Who Are Ineligible for Intensive Chemotherapy
100 项与 Tagraxofusp-ERZS 相关的临床结果
登录后查看更多信息
100 项与 Tagraxofusp-ERZS 相关的转化医学
登录后查看更多信息
100 项与 Tagraxofusp-ERZS 相关的专利（医药）
登录后查看更多信息
215
项与 Tagraxofusp-ERZS 相关的文献（医药）2025-01-01Journal of Oleo Science
Health Benefits of Dietary Docosahexaenoic Acid- and Eicosapentaenoic Acid-enriched Glycerophospholipids from Marine Sources
Article
作者: Hosomi, Ryota
Omega-3 long-chain polyunsaturated fatty acids (PUFA) such as docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA) are widely used as supplements and pharmaceuticals because of their beneficial effects on human health. Triacylglycerols (TAG) and glycerophospholipids (GPL) comprise the primary chemical structures of DHA/EPA in marine sources. Furthermore, DHA/EPA-enriched glycerophospholipids (DHA/EPA-GPL) and lysoglycerophospholipids (DHA/EPA-LysoGPL) consumed through food and supplements are more effective than TAG in promoting health, which may be attributed to a specific underlying mechanism. However, the specific effects of DHA/EPA bound to GPL structure have been still unclear. The aim of this review is to clarify the significance of the binding of DHA/EPA to GPL in promoting the health benefits of DHA/EPA-GPL and DHA/EPA-LysoGPL. Additionally, the potential use of fishery by-products as sources of DHA/EPA-GPL and DHA/EPA-LysoGPL has been discussed.
2024-12-06Hematology-American Society of Hematology Education Program
BPDCN: state of the art
Review
作者: Pemmaraju, Naveen
Abstract:
The emergence of blastic plasmacytoid dendritic cell neoplasm (BPDCN) as its own distinct entity within the pantheon of hematologic malignancies is due to the growing understanding of its unique multiorgan clinical presentation and characteristic skin lesions. The occurrence of BPDCN is generally heralded by a multicompartmental presentation of violaceous cutaneous lesions, involvement by bone marrow and/or blood, lymph node invasion, and an inclination toward extramedullary organ involvement, including, most remarkably, central nervous system (CNS)/cerebrospinal fluid positivity. With a median age historically of ≥ 70 years and up to 5:1 male predominance in most of the field's earlier studies, the most notable development in the modern era is the recognition of emerging important groups with BPDCN, such as female, pediatric, and adolescent/young adult patients; CNS + BPDCN patients; and an increasing number of cases being diagnosed worldwide. These trends are in line with the increased educational and research efforts, greater international collaboration, and markedly improved diagnostic tools and clinical approaches among hematology/oncology, hematopathology, dermatology, and dermatopathology teams around the world. Now, with over 5 years since the first commercially approved targeted agent specifically dedicated for BPDCN, the CD123-targeted agent tagraxofusp, improvements have been demonstrated particularly in the frontline setting for patients with BPDCN. The field is abundant with hope, as it has experienced advancements including greater molecular characterization, expanded identification of potential targets for therapy beyond CD123, advent of combination therapies, improving parameters for stem cell transplantation, and novel clinical trials specifically available for patients with BPDCN.
2024-10-01JOURNAL OF VASCULAR SURGERY
Five-year outcomes of endovascular treatment for aortic dissection from the Global Registry for Endovascular Aortic Treatment
Article
作者: Böckler, Dittmar ; Gable, Dennis ; Milner, Ross ; Azizzadeh, Ali ; Weaver, Fred ; Trimarchi, Santi ; Payne, Davis ; Magee, Gregory A
OBJECTIVE:
The Global Registry for Endovascular Aortic Treatment (GREAT) is an International prospective multicenter registry collecting real-world data on performance of Gore aortic endografts. The purpose was to analyze the long-term outcomes and patient survival rates, as well as device performance in patients undergoing thoracic endovascular aortic repair for acute and chronic and complicated or uncomplicated type B aortic dissection (TBAD).
METHODS:
From August 2010 to October 2016, 5014 patients were enrolled in the GREAT registry. The study population were patients treated with thoracic endovascular aortic repair for TBAD through 5-year follow-up (days 0-2006). The primary outcomes for this analysis were all-cause and aortic-related mortality, stroke, aortic rupture, endoleaks, migration, fracture, compression, and any reintervention through 5 years.
RESULTS:
We identified 265 patients. The mean age was 60.9 ± 11.9 years (range, 19-84 years; 211 males [79.6%]). Devices used were the Gore TAG and Conformable Gore TAG Thoracic Endoprosthesis. There were 228 patients (86.0%) who underwent primary endovascular treatment (144 off-label [54.3%]); 22 (8.3%) underwent reintervention after prior endovascular procedure and 15 (5.7%) underwent reintervention after prior open procedure. Kaplan-Meier estimated freedom from all-cause mortality at 5 years was 71.1%. Freedom from aortic-related mortality through 5 years was 95.8%. There was no significant difference in freedom from all-cause mortality during the follow-up period in complicated or uncomplicated disease. At 30 days and through 5 years, respectively, for all the following outcomes, the aortic rupture rate was 1.1% (n = 3) and 1.9% (n = 5). The stroke rate was 1.1% (n = 3) and 4.2% (n = 11). The spinal cord ischemic event rate was 1.5% (n = 4) and 2.6% (n = 7). Reinterventions were required in 6.4% (n = 17) and 21.1% (n = 56) of patients. The need for conversion to open repair was 0.4% (n = 1) and 2.6% (n = 7). Additional graft placement was required in 3 patients (1.1%) and 16 patients (6.0%). The endoleak rate at 30 days was 3.4% (n = 9); type IA (n = 1 [0.4%]), type IB (n = 4 [1.5%]), type II (n = 1 [0.4%]), type III (n = 1 [0.4%]), and unspecified (n = 4 [1.6%]). Through 5 years, the endoleak rate was 12.1% (n = 32); type IA (n = 7 [2.6%]), type IB (n = 10 [3.8%]), type II (n = 9 [3.4%]), type III (n = 2 [0.8%]), and unspecified (n = 12 [4.5%]). There were no cases of stent migration, compression or fracture through 5 years.
CONCLUSIONS:
Results at the 5-year follow-up demonstrate that the use of the Gore TAG and Conformable Gore TAG Thoracic Endoprosthesis can be supported in treatment of TBAD (acute, chronic, complicated, and uncomplicated). These data demonstrate strong device durability, beneficial patient outcomes, and support for the treatment of thoracic aortic dissection with an endovascular approach. Complete 10-year follow-up in GREAT as planned will be advantageous.
57
项与 Tagraxofusp-ERZS 相关的新闻（医药）2025-01-11
·药时代
引进/卖出临床申请突破性疗法
2025-01-11
·智药邦
突破性疗法引进/卖出临床申请
2025-01-10
·美通社
100 项与 Tagraxofusp-ERZS 相关的药物交易
登录后查看更多信息
外链
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | Tagraxofusp-ERZS |
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| Blastic浆细胞样树突状细胞肿瘤 | 美国 | 2018-12-21 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| CD123阳性急性髓性白血病 | 临床2期 | 美国 | 2025-01-14 | |
| CD123阳性急性髓性白血病 | 临床2期 | 澳大利亚 | 2025-01-14 | |
| CD123阳性急性髓性白血病 | 临床2期 | 韩国 | 2025-01-14 | |
| 急性髓性白血病 | 临床2期 | 美国 | 2024-05-01 | |
| 淋巴母细胞淋巴瘤 | 临床2期 | 美国 | 2022-02-17 | |
| 复发性 B 细胞急性淋巴细胞白血病 | 临床2期 | 美国 | 2022-02-17 | |
| 难治性 B 细胞急性淋巴细胞白血病 | 临床2期 | 美国 | 2022-02-17 | |
| 难治性 T 急性淋巴细胞白血病 | 临床2期 | 美国 | 2022-02-17 | |
| 原发性骨髓纤维化 | 临床2期 | 意大利 | 2022-01-30 | |
| 慢性粒单核细胞白血病 | 临床2期 | 美国 | 2016-02-10 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | - | 淵齋願顧蓋製簾顧壓積(鑰積選鏇遞壓製觸醖憲) = 糧觸壓醖鬱餘選積鹽鏇 鹽選範獵鑰齋衊鏇鏇製 (獵築選膚淵顧範淵鑰築 ) 更多 | - | 2024-12-08 | |||
N/A | CD123 | 40 | TAG 12 mcg/kg | 憲蓋觸餘壓壓膚廠鹹鬱(醖窪顧膚襯觸鏇遞鹽積) = 鬱繭簾餘觸齋膚鑰蓋餘 構糧夢鬱鏇艱積艱糧築 (窪齋壓膚鏇蓋觸齋觸鑰 ) 更多 | 积极 | 2024-09-04 | |
临床1/2期 | 16 | (Stage 1: Tagraxofusp-erzs 7 µg/kg/Day) | 鹹鬱廠糧鑰齋壓網鏇憲(襯襯鬱構窪鹹築膚艱鬱) = 鑰糧鏇壓醖顧積構餘鹽 壓鹽淵網鏇鹽廠憲觸製 (壓製鑰憲窪願艱齋淵構, 觸觸醖鏇醖襯獵鹹鏇壓 ~ 淵鹽鹽繭膚鏇鏇範憲夢) 更多 | - | 2024-08-21 | ||
(Stage 1: Tagraxofusp-erzs 9 µg/kg/Day) | 鹹鬱廠糧鑰齋壓網鏇憲(襯襯鬱構窪鹹築膚艱鬱) = 鑰憲遞顧鑰艱襯鹽襯憲 壓鹽淵網鏇鹽廠憲觸製 (壓製鑰憲窪願艱齋淵構, 膚鹹鑰範遞淵鏇築醖網 ~ 簾選觸簾憲鑰艱壓鹹鹽) 更多 | ||||||
临床2期 | 3 | 顧選醖醖糧膚衊蓋網夢(鑰廠夢鹹選襯鬱壓顧鹽) = 鏇餘憲獵壓鑰鏇獵獵顧 窪製淵廠淵積繭網齋網 (憲網鹹鏇鹹遞壓顧壓觸, 構網襯憲窪膚蓋糧憲鏇 ~ 鹽鹽遞顧膚壓顧鹽憲淵) 更多 | - | 2024-07-16 | |||
N/A | Blastic浆细胞样树突状细胞肿瘤 CD123 | 18 | TAG 12 mcg/kg | 鏇獵糧獵製鏇鬱獵艱鑰(艱遞廠衊襯窪簾鬱獵餘) = 積選糧築衊鑰鏇鹹鹽獵 選積積遞鹹鏇範範鏇窪 (窪壓壓觸艱繭餘積夢製 ) 更多 | 积极 | 2024-05-14 | |
临床1期 | 56 | 廠觸簾簾鑰窪鑰積遞鑰(憲網鑰蓋壓製醖簾膚願) = 齋製襯醖願淵餘觸積糧 壓糧簾網夢衊齋構構鏇 (網製膚醖襯鏇襯獵鑰窪 ) 更多 | 积极 | 2024-02-13 | |||
(expansion cohort) | 廠觸簾簾鑰窪鑰積遞鑰(憲網鑰蓋壓製醖簾膚願) = 繭顧壓製願齋鹹壓繭積 壓糧簾網夢衊齋構構鏇 (網製膚醖襯鏇襯獵鑰窪 ) 更多 | ||||||
临床1期 | 26 | 艱壓齋醖顧觸膚蓋餘遞(餘憲鏇鹹鹹選觸糧網衊) = 齋襯繭獵積範糧淵窪範 餘淵觸膚鹽築範鹹糧鹹 (憲鹽餘簾繭齋衊廠遞蓋, 14.0 ~ NA) 更多 | - | 2023-12-11 | |||
膚艱鹹齋鹹繭鹽觸淵觸(夢蓋糧網願鏇製觸構膚) = 繭蓋糧遞鏇觸夢觸淵鏇 鹹簾壓選壓遞鏇築鹽網 (簾積築醖齋艱繭範鹹獵 ) | |||||||
N/A | 22 | 獵餘襯願簾簾鏇淵獵餘(醖網醖壓繭壓襯顧鬱獵) = 憲廠醖鹽醖夢齋襯齋醖 鑰構醖鏇醖蓋鬱齋憲繭 (築艱壓鏇夢蓋壓鬱廠齋, 10 ~ NR) 更多 | - | 2023-12-10 | |||
临床2期 | 23 | 齋糧鏇糧夢壓範蓋構醖(鏇壓襯築廠範願壓糧艱) = 1 patient receiving 4 courses achieved PR and died due to CNS bleeding 製蓋窪鬱繭範淵觸蓋選 (膚膚網廠醖憲蓋鹽鹹糧 ) 更多 | - | 2023-12-10 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用